AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$TRVI

Heffernan Michael Thomas sold $596K of TRVI

Heffernan Michael Thomas sold 39,473 shares of Trevi Therapeutics, Inc. (TRVI) at an average of $15.09 ($15.09–$15.88, $0.60M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heffernan Michael Thomas
Published Sep 17, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRVI
Bearish
medium confidence
Mentioned
$TRVI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRVIBearishLow
01

Why it matters

While the sale is modest, it provides fresh data on insider sentiment.

02

Market read

New insider sale adds to the flow of information for TRVI investors; likely limited price effect.

03

What to watch

Director may be diversifying holdings; no change in company fundamentals.

Relevance 4/10Novelty 4/10Timing: filing date 2026-09-17

Background

Form 4 filing discloses insider transactions; traders monitor for material signals.

Company-level read

Ticker impact

$TRVIBearishMedium confidence
Context

Director Heffernan Michael Thomas sold 39,473 shares (~$596K) via a 10b5‑1 plan on 2026‑09‑15.

Expected impact

Potential modest dip of 1‑2% in the near term.

Evidence & confidence

A director offloading a sizable block signals possible concerns, but the amount is modest relative to market cap.

Market effects

Sector

Biotech sector may see slight pressure as insider sales are watched closely.

Regional

U.S. equity markets, particularly small‑cap biotech segment.

Global

Limited; impact confined to TRVI and its niche investors.

Counterpoint

What could challenge this read

The sale could be routine liquidity planning under a 10b5‑1, not a bearish signal.

Key entities

  • Company
    Trevi Therapeutics, Inc.

    US‑listed biotech (ticker TRVI).

  • Individual
    Heffernan Michael Thomas

    Director of Trevi Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRVI insider trading history →

Related articles

AUG 6
$TRVIMed

Trevi Therapeutics, Inc. (TRVI): Results of Operations and Financial Condition

Trevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in t

SEC EDGAR 8-K7 min
JUL 17
$TRVIMed

Can’t hack it? Bellus tolls for GSK phase III cough drug

GSK plc reported phase III results for camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. According to GSK, the Calm-1 trial met its primary endpoint, with 50 mg twice daily reducing 24-hour cough frequency versus placebo at week 12. GSK’s walk-away from the program also highlighted Trevi Therapeutics’ Haduvio, which had positive phase II data in June.

bioworld.com4 min
JUL 17
$TRVIMed

Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference

Trevi Therapeutics shares rose 13.10% to $19.64 after the company presented clinical data on Haduvio (nalbuphine extended-release) for chronic cough at the European Respiratory Society Cough Conference in London. Trevi said results show a statistically significant cough-frequency reduction across IPF-related and refractory chronic cough. Analysts cited a $21.10 average target; Trevi also reported a June $162 million net offering.

ibtimes.com.au6 min